Cyrus Reed: Hey, how was the rest of your week — because mine ended with a press release that made me genuinely question everything I thought I knew about first-line lung cancer.
Iris Holm: OptiTROP-Lung06.
Cyrus Reed: OptiTROP-Lung06. Phase 3 trial, sac-TMT plus pembrolizumab versus the chemo-immunotherapy backbone in PD-L1-negative non-squamous NSCLC — and it won. Positive primary endpoint. And then Leerink Partners goes and calls it the first direct proof-of-concept that an ADC can replace platinum-based chemotherapy in a first-line regimen, and I'm sitting there going — okay but cisplatin and carboplatin have been the backbone of this disease for like thirty-plus years. That's not a small claim.
Iris Holm: It's not. Now — the drug in question: sacituzumab tirumotecan, developed by Sichuan Kelun-Biotech, licensed to Merck for $1.4 billion in December 2022. Merck's fingerprints are on both the asset and the combination — sac-TMT runs alongside pembrolizumab, which is Keytruda, which is Merck's biggest franchise.
Cyrus Reed: No way — so the 'replacement' is bundled with the drug it's supposedly liberating patients from needing.
Iris Holm: Exactly the tension. Platinum exits, Keytruda stays, sac-TMT enters. That's the structure. Call that replacing platinum if you want — but name what you mean first.
Cyrus Reed: So the episode is basically: what does 'replacing' actually mean here, and who benefits from the framing?
Iris Holm: 'Replacing' is the word. That's where we start.
Cyrus Reed: But before we even get to the 'replacing' debate — I don't think I actually understand what makes this drug different from chemo in the first place. Like, mechanically. Why is TROP2 the thing?
Iris Holm: Platinum-based chemo is a carpet bomb. Hits everything dividing — cancer, hair follicles, gut lining, all of it. sac-TMT is a guided missile. It locks onto TROP2, a protein flag that lung cancer cells tend to overexpress, and delivers the kill payload — KL610023, a topoisomerase I inhibitor — directly there. That's the whole mechanism in one sentence.
Cyrus Reed: Wait — so the antibody part finds the flag, and then the payload detonates on contact?
Iris Holm: Essentially. Which is why you can pair it with pembrolizumab without stacking toxicities the way platinum does. That's new. That's actually new.
Cyrus Reed: Okay but — wait, no — here's what I keep tripping on. Lung05, the PD-L1-positive trial, showed a 65% reduction in risk of progression or death versus pembrolizumab alone. That's not a small number. That was at ASCO 2026, published in The Lancet. But Lung06 covers PD-L1-negative patients, where immunotherapy basically offers limited benefit on its own anyway. So they've — I mean, together those two trials cover the whole driver-gene-negative non-squamous population, right? That's actually the genuinely novel piece, isn't it? Two trials, two populations, full coverage.
Iris Holm: That's the real architecture. And both show positive OS trends. But — both OS datasets are immature. That's the load-bearing asterisk.
Cyrus Reed: And PFS and OS have decoupled in lung immunotherapy before.
Iris Holm: Repeatedly. Now — the drug does have one clean Phase 3 win with mature OS. TroFuse-005, endometrial cancer. PFS and OS both met. That's evidence the drug works. But lung cancer is a harder claim — different tumor biology, different patient selection, different competitive standard.
Cyrus Reed: So the precedent exists, but it doesn't transfer automatically. The PFS win in lung is real — the OS story is still being written.
Iris Holm: But that's exactly where the wrong take lives — and it's circulating right now. The 'replacing platinum' frame implies the whole old regimen is gone. It isn't. Look at Lung06: sac-TMT plus pembrolizumab versus the chemo-immunotherapy backbone. Pembrolizumab is in both arms. Keytruda doesn't leave the room. Only the platinum leaves.
Cyrus Reed: Wait — so the control arm still has Keytruda in it?
Iris Holm: Keytruda-anchored in both arms. sac-TMT is a better chemo partner for pembrolizumab. That's the actual claim. Narrower than a paradigm shift.
Cyrus Reed: But — I mean, isn't swapping platinum for an ADC still genuinely significant? Like, platinum toxicity is the thing patients actually suffer from. Hair loss, nephrotoxicity, the whole brutal package. If sac-TMT removes that and keeps the efficacy signal — wait, actually, is that less of a story just because Keytruda's still there?
Iris Holm: It's significant. I'm not disputing the clinical value. But Leerink called it 'first direct proof-of-concept' for replacing platinum — full stop. That framing implies the immunotherapy scaffold is optional. It isn't. The scaffold is Keytruda. Merck's scaffold.
Cyrus Reed: So the paradigm shift is actually — huh — a Keytruda upgrade, not a Keytruda exit.
Iris Holm: Now — MK-2870-004, trial NCT06074588. That one compares sac-TMT directly against chemotherapy, no pembrolizumab, in previously treated EGFR-mutant non-squamous NSCLC. That's where you'd test actual platinum replacement without the immunotherapy scaffold. That trial is still running. The ambition to replace platinum cleanly exists — the proof does not yet.
Cyrus Reed: No way — so the trial that would actually prove the 'replacing platinum' story isn't even the one everyone's citing.
Iris Holm: And we haven't even touched why Western regulators might not accept a China-sponsored population as a global standard-of-care label — that part gets worse. But right now: the framing matters. Oncologists read 'platinum replacement' and they're making prescribing inferences. Regulators read it and they're setting evidence bars. Call it what it is — a better chemo partner inside a Keytruda regimen — and those conversations change.
Cyrus Reed: And the 'better chemo partner' framing — that's where the patent cliff actually becomes the story, not just the backdrop. Because Keytruda's core patent is expiring, and Merck needs something to bundle Keytruda into a new first-line regimen so the franchise survives the cliff. The $1.4 billion they paid Kelun-Biotech in December 2022 — you close that deal, you run two trials that both structurally require pembrolizumab, and then in 2026 you get a readout that says Keytruda is still the indispensable backbone. That timing is — I mean, is that designed? Or is it just convenient?
Iris Holm: Designed or convenient — the incentive is the same either way.
Cyrus Reed: Right — but a tumor board oncologist in Hamburg, late 2026, flips open the Lung06 data. First question she asks isn't about PFS curves. It's — wait, was this trial run in China, on a Chinese patient population, against comparators that match what we actually use here? Because standard-of-care comparators in China and in Western Europe are not the same thing.
Iris Holm: That's not a small scrutiny gap. Both OptiTROP trials ran primarily in China under Kelun-Biotech's sponsorship. Western regulators — FDA, EMA — they have pressed hard before on exactly this. Whether trial populations generalize.
Cyrus Reed: No way — so the Hamburg oncologist's instinct is actually the regulatory question?
Iris Holm: It is the regulatory question. And it won't be framed as skepticism about Chinese science — it'll be framed as: does the control arm reflect Western standard of care? That's a legitimate bar. And it's unresolved.
Cyrus Reed: And that unresolved bar is exactly where the crowded ADC field gets interesting — because HER2, HER3, c-Met assets are all coming, probably with Western trial populations, and sac-TMT's 'first' status in first-line NSCLC might only be singular for, what, eighteen months before another readout lands and the comparison gets complicated?
Iris Holm: Which is the watch item. Not whether sac-TMT works — TroFuse-005 proved the drug works, mature OS in endometrial cancer. The watch item is whether Western regulators accept a China-conducted trial as sufficient for a global label before a HER2 or HER3 asset reads out with a more internationally distributed population.
Cyrus Reed: So the race isn't sac-TMT versus platinum. It's sac-TMT versus the next ADC that arrives with a trial the Hamburg tumor board doesn't have to interrogate.
Iris Holm: That's the question that stays open. Both OptiTROP-Lung05 and Lung06 — OS immature in both. When those data mature, there are exactly two stories. One: OS confirms the PFS signal, Western regulators accept the China-conducted population, and this is a genuine inflection point for ADCs in first-line lung. Two: OS disappoints. And then Lung06's legacy isn't 'first ADC to replace platinum' — it becomes the trial that proved PFS superiority matters less than we thought in this setting. That's a different kind of landmark.
Cyrus Reed: And — I mean, that second version is actually a warning about how we've been using PFS as a proxy in lung cancer immunotherapy this whole time. Like, not just for sac-TMT. For the whole class. How many treatment decisions are sitting on PFS data that hasn't been tested against mature OS yet?
Iris Holm: That's the one I don't have an answer to. Nobody does yet.
